- Home
- Publications
- Publication Search
- Publication Details
Title
Current Development Status of MEK Inhibitors
Authors
Keywords
-
Journal
MOLECULES
Volume 22, Issue 10, Pages 1551
Publisher
MDPI AG
Online
2017-09-27
DOI
10.3390/molecules22101551
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MEK inhibitors in oncology: a patent review (2015-Present)
- (2017) Debarshi Kar Mahapatra et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).
- (2017) Anuradha Krishnamurthy et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer
- (2017) David R. Gandara et al. Journal of Thoracic Oncology
- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- LGG-08. A PHASE II PROSPECTIVE STUDY OF SELUMETINIB IN CHILDREN WITH RECURRENT OR REFRACTORY LOW-GRADE GLIOMA (LGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
- (2017) Jason Fangusaro et al. NEURO-ONCOLOGY
- A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
- (2017) Anuradha Banerjee et al. NEURO-ONCOLOGY
- A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
- (2016) W. M. Tai et al. ANNALS OF ONCOLOGY
- A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
- (2016) David Jamieson et al. EUROPEAN JOURNAL OF CANCER
- A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
- (2016) Alex A. Adjei et al. INVESTIGATIONAL NEW DRUGS
- A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
- (2016) Lee S. Rosen et al. INVESTIGATIONAL NEW DRUGS
- Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent
- (2016) Jessica T. Leonard et al. Journal of Hematology & Oncology
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- Emerging therapeutic agents for lung cancer
- (2016) Bhagirathbhai Dholaria et al. Journal of Hematology & Oncology
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
- (2016) Jean-Luc Van Laethem et al. Targeted Oncology
- Absorption, metabolism and excretion of cobimetinib, an oral MEK inhibitor, in rats and dogs
- (2016) Ryan H. Takahashi et al. XENOBIOTICA
- Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
- (2015) Paola Queirolo et al. CANCER TREATMENT REVIEWS
- MEK inhibitors beyond monotherapy: current and future development
- (2015) Ian E Templeton et al. CURRENT OPINION IN PHARMACOLOGY
- BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
- (2015) Juliet Richman et al. EXPERT OPINION ON PHARMACOTHERAPY
- Nivolumab plus ipilimumab in the treatment of advanced melanoma
- (2015) Katy K. Tsai et al. Journal of Hematology & Oncology
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
- (2014) H. Y. Lim et al. CLINICAL CANCER RESEARCH
- Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
- (2014) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- Prospects for MEK inhibitors for treating cancer
- (2014) Juan Martin-Liberal et al. Expert Opinion On Drug Safety
- Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro
- (2013) Emanuel Haasbach et al. ANTIVIRAL RESEARCH
- Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib)
- (2013) J. El-Hoss et al. BONE
- Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
- (2013) M Beloueche-Babari et al. BRITISH JOURNAL OF CANCER
- CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo
- (2013) Dong Joon Kim et al. CARCINOGENESIS
- Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
- (2013) N. Jain et al. CLINICAL CANCER RESEARCH
- A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies
- (2013) Roger B. Cohen et al. EUROPEAN JOURNAL OF CANCER
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- BRAF inhibitors in cancer therapy
- (2013) Carolina Hertzman Johansson et al. PHARMACOLOGY & THERAPEUTICS
- MEK in cancer and cancer therapy
- (2013) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts
- (2012) Edna F. Choo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
- (2012) S. Leijen et al. CLINICAL CANCER RESEARCH
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
- (2012) M. Martinez-Garcia et al. CLINICAL CANCER RESEARCH
- 502 Preclinical Pharmacokinetics and Efficacy Assessment of a Potent and Selective MEK Inhibitor, GDC-0623
- (2012) E. Choo et al. EUROPEAN JOURNAL OF CANCER
- 608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors
- (2012) A. Naing et al. EUROPEAN JOURNAL OF CANCER
- 616 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma
- (2012) J.P. Delord et al. EUROPEAN JOURNAL OF CANCER
- 604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial
- (2012) A. Awada et al. EUROPEAN JOURNAL OF CANCER
- 600 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors
- (2012) N. Houédé et al. EUROPEAN JOURNAL OF CANCER
- Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
- (2012) Brigette B. Y. Ma et al. INVESTIGATIONAL NEW DRUGS
- Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by 18F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials
- (2012) F. Kraeber-Bodere et al. JOURNAL OF NUCLEAR MEDICINE
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)
- (2012) Kenneth D. Rice et al. ACS Medicinal Chemistry Letters
- Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
- (2011) Qing Dong et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent
- (2011) Yoshiaki Isshiki et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
- (2011) Peter D. Boasberg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Mitogen-activated protein kinase in the amygdala plays a critical role in lithium chloride-induced taste aversion learning
- (2011) Bumsup Kwon et al. NEUROBIOLOGY OF LEARNING AND MEMORY
- Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)
- (2011) Hiroyuki Abe et al. ACS Medicinal Chemistry Letters
- Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
- (2010) Gajanan S. Inamdar et al. BIOCHEMICAL PHARMACOLOGY
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
- (2010) E. B. Haura et al. CLINICAL CANCER RESEARCH
- Emerging MEK inhibitors
- (2010) James A McCubrey et al. EXPERT OPINION ON EMERGING DRUGS
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression
- (2010) Lucy Lee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models
- (2010) S. Daouti et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor
- (2010) Edna F. Choo et al. XENOBIOTICA
- RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
- (2009) C. Iverson et al. CANCER RESEARCH
- AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
- (2009) Hung Huynh et al. JOURNAL OF HEPATOLOGY
- PD98059, a specific MAP kinase inhibitor, attenuates multiple organ dysfunction syndrome/failure (MODS) induced by zymosan in mice
- (2009) Rosanna Di Paola et al. PHARMACOLOGICAL RESEARCH
- The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
- (2008) Stephen D. Barrett et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Putative allosteric MEK1 and MEK2 inhibitors
- (2008) Steve Price EXPERT OPINION ON THERAPEUTIC PATENTS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started